Center on Democracy, Development, and the Rule of Law
Center for International Security and Cooperation
Center on Food Security and the Environment
Stanford Health Policy
The Europe Center
Walter H. Shorenstein Asia-Pacific Research Center
Program on Energy and Sustainable Development
Rural Education Action Program
Stanford Program on International and Cross-Cultural Education
Inter-University Center for Japanese Language Studies
Ford Dorsey Program in International Policy Studies
Center for Innovation in Global Health
Stanford Center at Peking University
About CISAC
Mailing List
@StanfordCISAC
Facebook
Hau Liu, MD, MPH, MBA
Associate Chief of Endocrinology, Co-Director of Chronic Care Management at Valley Medical Center, San Jose and Stanford Health Policy Trainee (former); Stanford Health Policy Adjunct AffiliateView Hau Liu's bio, list of research, recent publications and events »
September 3rd, 2012
Little evidence of health benefits from organic foods, Stanford study finds
CHP/PCOR in the news: Stanford Press ReleaseYou’re in the supermarket eyeing a basket of sweet, juicy plums. You reach for the conventionally grown stone fruit, then decide to spring the extra $1/pound for its organic cousin. You figure you’ve just made the healthier decision by choosing the organic product — but new findings from Stanford University cast some doubt on your thinking. Read more »
May 22nd, 2007
Human growth hormone is no fountain of youth
CHP/PCOR in the newsIn this Q&A piece on human growth hormone, a study led by CHP/PCOR adjunct affiliate Hau Liu is referenced. The study found that there is no data to suggest that giving growth hormone to an otherwise health person will make him or her live longer.
- » Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly
- » Arizona Republic: "Human growth hormone is no fountain of youth"
- » Syndey Morning Herald: "Evidence Short on Growth Hormone" (9/20/2007)
January 15th, 2007
Fellow Hau Liu Receives Wide Media Coverage on Human Growth Hormone Study
CHP/PCOR in the news: CHP/PCOR Quarterly Update on January 15, 2007CHP/PCOR fellow Hau Liu was one of the authors in a study on the effect of human growth hormone (HGH) therapy. The meta-analysis examines the efficacy of HGH.
Read more »
August 19th, 2006
Citing CHP/PCOR study, Indiana drops free osteoporosis screening program
CHP/PCOR in the newsIndiana's state health department has ended a free osteoporosis screening program, citing a recently published CHP/PCOR study which questioned the accuracy and value of heel ultrasound, the type of machine used in the program.
Read more »
June 10th, 2006
New osteoporosis drug may not be worth its high price, study finds
CHP/PCOR Press ReleaseA new osteoporosis drug that rebuilds lost bone, sold as the brand name Forteo, is not cost-effective compared with the most commonly prescribed therapy, alendronate (brand name Fosamax), due largely to the new drug's much higher cost, finds a study by CHP/PCOR researchers. Fosamax costs about $900 a year, while Forteo costs $6,700. 
Read more »